Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 5

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Diabetic neuropathy

Recruiting

A study testing capsaicin patches compared to placebo for patients with painful diabetic nerve damage to assess effects on nerve symptoms and nerve fibers

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capsaicin
  • Sponsor:Deutsche Diabetes Forschungsgesellschaft e.V.

Acute myocardial infarction+1

Recruiting

Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Humanitas Mirasole S.p.A.

Diabetes mellitus+1

Recruiting

A study of estradiol and progesterone treatment for blood sugar control in women with type 1 or type 2 diabetes during or after menopause

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Amsterdam UMC Stichting

Coronary artery disease+1

Recruiting

Study of dapagliflozin and semaglutide to reverse prediabetes to normal blood sugar levels in patients with coronary artery disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Region Midtjylland

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Palliative care+1

Recruiting

Study of testosterone supplementation to improve quality of life in male patients receiving palliative care who have androgen deficiency

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Testosterone decanoate
  • Sponsor:Institut Jules Bordet

Adrenogenital syndrome

Recruiting

Study of crinecerfont oral solution in children under 2 years old with congenital adrenal hyperplasia to evaluate safety and how the drug works in the body

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Crinecerfont

Diabetic retinal oedema

Recruiting

Study of faricimab treatment to improve vision in patients with diabetic macular edema using adaptive optics imaging

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Diabetic retinal oedema

Recruiting

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim International GmbH

Glucose tolerance impaired

Recruiting

Evaluation of controlled-ileal-release nicotinic acid tablets compared to placebo for treating people with prediabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinic acid
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.